ZIM
EPZM

Zacks Investment Management’s Epizyme, Inc EPZM Stock Holding History

Zacks Investment Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-17,003
Closed -$174K – 751
2016
Q2 		$174K Hold
17,003
– – 0.01% 584
2016
Q1 		$206K Buy
+17,003
New +$172K 0.01% 549

Other funds holding EPZM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Zacks Investment Management's EPZM Position: Q3 2016 in Review

Zacks Investment Management sold out of Epizyme, Inc (EPZM) in Q3 2016, closing a stake of 17,003 shares — an estimated $174K sold.

Zacks Investment Management first reported a position in EPZM in Q1 2016 and held it in 2 quarters. The position peaked at $206K in Q1 2016. 97 funds tracked by Wall St. Rank hold EPZM as of Q3 2016.

  • Zacks Investment Management reported no remaining Epizyme, Inc position as of Q3 2016 after selling out during the quarter.
  • Zacks Investment Management sold 17,003 Epizyme, Inc shares in Q3 2016, an estimated $174K.
  • Zacks Investment Management first reported a position in Epizyme, Inc in Q1 2016 and held it in 2 quarters.
  • Zacks Investment Management's Epizyme, Inc position peaked at $206K in Q1 2016.
  • 97 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2016.

Based on Zacks Investment Management's 13F filing for Q3 2016, filed 14 Nov 2016.